Literature DB >> 8040342

Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3.

D A Sanan1, K H Weisgraber, S J Russell, R W Mahley, D Huang, A Saunders, D Schmechel, T Wisniewski, B Frangione, A D Roses.   

Abstract

Late-onset and sporadic Alzheimer's disease are associated with the apolipoprotein E (apoE) type 4 allele expressing the protein isoform apoE4. Apolipoprotein E binds avidly to beta amyloid (A beta) peptide, a major component of senile plaque of Alzheimer's disease, in an isoform-specific manner. The apoE4 isoform binds to A beta peptide more rapidly than apoE3. We observed that soluble SDS-stable complexes of apoE3 or apoE4, formed by coincubation with A beta peptide, precipitated after several days of incubation at 37 degrees C with apoE4 complexes precipitating more rapidly than apoE3 complexes. A beta(1-28) and A beta(1-40) peptides were incubated in the presence or absence of apoE3, apoE4, or bovine serum albumin for 4 d at 37 degrees C (pH 7.3). Negative stain electron microscopy revealed that the A beta peptide alone self-assembled into twisted ribbons containing two or three strands but occasionally into multistranded sheets. The apoE/A beta coincubates yielded monofibrils 7 nm in diameter. ApoE4/A beta coincubates yielded a denser matrix of monofibrils than apoE3/A beta coincubates. Unlike purely monofibrillar apoE4/A beta coincubates, apoE3/A beta coincubates also contained double- and triple-stranded structures. Both apoE isoforms were shown by immunogold labeling to be uniformly distributed along the A beta peptide monofibrils. Monofibrils appeared earlier in apoE4/A beta than in apoE3/A beta in time-course experiments. Thus apoE3 and apoE4 each interact with beta amyloid peptide to form novel monofibrillar structures, apoE4 more avidly, a finding consistent with the biochemical and genetic association between apoE4 and Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8040342      PMCID: PMC296168          DOI: 10.1172/JCI117407

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  25 in total

1.  Isolation and characterization of apolipoprotein E.

Authors:  S C Rall; K H Weisgraber; R W Mahley
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

2.  Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins.

Authors:  R E Pitas; J K Boyles; S H Lee; D Foss; R W Mahley
Journal:  Biochim Biophys Acta       Date:  1987-01-13

3.  Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain.

Authors:  R E Pitas; J K Boyles; S H Lee; D Hui; K H Weisgraber
Journal:  J Biol Chem       Date:  1987-10-15       Impact factor: 5.157

4.  Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro.

Authors:  B P Nathan; S Bellosta; D A Sanan; K H Weisgraber; R W Mahley; R E Pitas
Journal:  Science       Date:  1994-05-06       Impact factor: 47.728

5.  Synthetic peptide homologous to beta protein from Alzheimer disease forms amyloid-like fibrils in vitro.

Authors:  D A Kirschner; H Inouye; L K Duffy; A Sinclair; M Lind; D J Selkoe
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

6.  In vitro formation of amyloid fibrils from two synthetic peptides of different lengths homologous to Alzheimer's disease beta-protein.

Authors:  E M Castaño; J Ghiso; F Prelli; P D Gorevic; A Migheli; B Frangione
Journal:  Biochem Biophys Res Commun       Date:  1986-12-15       Impact factor: 3.575

7.  Ten to fourteen residue peptides of Alzheimer's disease protein are sufficient for amyloid fibril formation and its characteristic x-ray diffraction pattern.

Authors:  P D Gorevic; E M Castano; R Sarma; B Frangione
Journal:  Biochem Biophys Res Commun       Date:  1987-09-15       Impact factor: 3.575

8.  Nerve injury stimulates the secretion of apolipoprotein E by nonneuronal cells.

Authors:  G J Snipes; C B McGuire; J J Norden; J A Freeman
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

9.  Lipoprotein uptake by neuronal growth cones in vitro.

Authors:  M J Ignatius; E M Shooter; R E Pitas; R W Mahley
Journal:  Science       Date:  1987-05-22       Impact factor: 47.728

10.  Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system.

Authors:  J K Boyles; R E Pitas; E Wilson; R W Mahley; J M Taylor
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

View more
  99 in total

1.  Expression of human apolipoprotein E3 or E4 in the brains of Apoe-/- mice: isoform-specific effects on neurodegeneration.

Authors:  M Buttini; M Orth; S Bellosta; H Akeefe; R E Pitas; T Wyss-Coray; L Mucke; R W Mahley
Journal:  J Neurosci       Date:  1999-06-15       Impact factor: 6.167

2.  Alpha-1-antichymotrypsin promotes beta-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease.

Authors:  L N Nilsson; K R Bales; G DiCarlo; M N Gordon; D Morgan; S M Paul; H Potter
Journal:  J Neurosci       Date:  2001-03-01       Impact factor: 6.167

3.  Apolipoprotein E forms stable complexes with recombinant Alzheimer's disease beta-amyloid precursor protein.

Authors:  C Haas; P Cazorla; C D Miguel; F Valdivieso; J Vázquez
Journal:  Biochem J       Date:  1997-07-01       Impact factor: 3.857

4.  The modulating effect of mechanical changes in lipid bilayers caused by apoE-containing lipoproteins on Aβ induced membrane disruption.

Authors:  Justin Legleiter; John D Fryer; David M Holtzman; Andtomasz Kowalewski
Journal:  ACS Chem Neurosci       Date:  2011-10-19       Impact factor: 4.418

5.  Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons.

Authors:  Y Huang; X Q Liu; T Wyss-Coray; W J Brecht; D A Sanan; R W Mahley
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

Review 6.  Dissecting Complex and Multifactorial Nature of Alzheimer's Disease Pathogenesis: a Clinical, Genomic, and Systems Biology Perspective.

Authors:  Puneet Talwar; Juhi Sinha; Sandeep Grover; Chitra Rawat; Suman Kushwaha; Rachna Agarwal; Vibha Taneja; Ritushree Kukreti
Journal:  Mol Neurobiol       Date:  2015-09-09       Impact factor: 5.590

Review 7.  Single cell gene expression profiling in Alzheimer's disease.

Authors:  Stephen D Ginsberg; Shaoli Che; Scott E Counts; Elliott J Mufson
Journal:  NeuroRx       Date:  2006-07

8.  Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century.

Authors:  Wing-Hin Lee; Ching-Yee Loo; Mary Bebawy; Frederick Luk; Rebecca S Mason; Ramin Rohanizadeh
Journal:  Curr Neuropharmacol       Date:  2013-07       Impact factor: 7.363

9.  Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target.

Authors:  Shiming Ye; Yadong Huang; Karin Müllendorff; Liming Dong; Gretchen Giedt; Elaine C Meng; Fred E Cohen; Irwin D Kuntz; Karl H Weisgraber; Robert W Mahley
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-12       Impact factor: 11.205

Review 10.  Use of genetic variation as biomarkers for Alzheimer's disease.

Authors:  Christiane Reitz; Richard Mayeux
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.